A recent phase III study showed that osimertinib treatment significantly increased progression-free survival (median PFS, 39.1 months for osimertinib vs. 5.6 months for placebo) in patients with unresectable stage III EGFR-mutated NSCLC who did not experience progression during or after chemoradiotherapy (38). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.